- Lewis Chodosh, University of Pennsylvania
E2F4 transcription factor activity in tumors can be used to predict the survival outcomes of breast cancer patients, providing a prognostic molecular signature with potential for use across many clinical contexts.
Howell and colleagues from the BCC risk-and-prevention panel report on how adding new, but available, information to current risk models could ultimately better predict a woman’s individual breast cancer risk.
Digitized mammographic images contain computer-extractable information of the parenchymal pattern not captured during routine radiologic interpretation, which have the potential to distinguish between BRCA1/2 mutation carriers and non-carriers.
A self-reported lack of physical activity was associated with shortened telomere length in early stage breast cancer survivors, suggesting a mechanism by which exercise can reduce cellular aging.
Chang, Perez, and colleagues, review recent data on different combinations of anti-human epidermal growth factor receptor (HER2) treatments, as part of the ‘recent advances in breast cancer treatment’ special series.
Rots and colleagues describe aberrant DNA methylation and histone modifications as two important classes of epigenetic mutations in breast cancer and review the preclinical and clinical epigenetic-based therapies currently being explored.
From the blog
Volume 16 Suppl 1 (3 November 2014)
Brighton, UK. 10-11 November 2014
Aims & scope
Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.
- 22 January 2015
- Palbociclib for breast cancer inches toward FDA approval
- 21 January 2015
- Manipulating Twist1's activity either to promote regeneration or target advanced tumors
- 15 January 2015
- A new opportunity for personalizing breast cancer treatment